n-methylaspartate has been researched along with Amentia in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Aljabali, AAA; Chellappan, DK; Dua, K; Goyal, R; Sarena, P; Sharma, A; Taliyan, R; Tambuwala, MM; Urmera, MT | 1 |
| Boustani, M; Fox, C; Moniz-Cook, E | 1 |
| Ansermot, N; Choong, E; Eap, CB; Noetzli, M | 1 |
| Aarsland, D; Ballard, C; Bullock, R; Corbett, A; Francis, PT; Hanney, M; Johnson, T; Jones, EL; Lawrence, D; Prasher, V; Tyrer, S; Williams, N; Yu, LM | 1 |
| Fischhof, PK | 1 |
| Litvinenko, IV | 1 |
| Perras, C | 1 |
| Christensen, MD; White, HK | 1 |
2 review(s) available for n-methylaspartate and Amentia
| Article | Year |
|---|---|
[Dementia and psychotic disorders in parkinsonism: common origin and new perspectives in therapy].
Topics: Dementia; Humans; N-Methylaspartate; Neurotransmitter Agents; Parkinson Disease; Psychotic Disorders; Receptors, N-Methyl-D-Aspartate | 2004 |
Dementia assessment and management.
Topics: Activities of Daily Living; Advance Care Planning; Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Dementia; Dementia, Vascular; Humans; Lewy Body Disease; Long-Term Care; Medical History Taking; Middle Aged; N-Methylaspartate; Neurologic Examination; Nutrition Therapy; Physical Examination; Practice Guidelines as Topic; Safety; Social Support | 2007 |
1 trial(s) available for n-methylaspartate and Amentia
| Article | Year |
|---|---|
Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Alzheimer Disease; Cognition; Dementia; Double-Blind Method; Down Syndrome; Female; Humans; Male; Memantine; Middle Aged; N-Methylaspartate | 2012 |
5 other study(ies) available for n-methylaspartate and Amentia
| Article | Year |
|---|---|
Chronic Light-Distorted Glutamate-Cortisol Signaling, Behavioral and Histological Markers, and Induced Oxidative Stress and Dementia: An Amelioration by Melatonin.
Topics: Animals; Biomarkers; Circadian Rhythm; Dementia; Dextromethorphan; Glutamic Acid; Hydrocortisone; Light; Melatonin; Mifepristone; N-Methylaspartate; Oxidative Stress; Rats; Rats, Wistar | 2022 |
Treatment of dementia: where is it going?
Topics: Cholinesterase Inhibitors; Dementia; Early Diagnosis; Humans; N-Methylaspartate; Psychotherapy; Quality of Life; Treatment Outcome | 2009 |
Simultaneous determination of antidementia drugs in human plasma for therapeutic drug monitoring.
Topics: Cholinesterase Inhibitors; Chromatography, Liquid; Dementia; Drug Monitoring; Drug Stability; Drug Therapy, Combination; Humans; Mass Spectrometry; N-Methylaspartate; Psychotropic Drugs; Receptors, N-Methyl-D-Aspartate; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction | 2011 |
Comments on the NMDA antagonist memantine.
Topics: Aged; Clinical Trials as Topic; Dementia; Dopamine Agents; Humans; Memantine; N-Methylaspartate | 2003 |
Memantine for treatment of moderate to severe Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Canada; Cholinesterase Inhibitors; Dementia; Diffusion of Innovation; Dopamine Agents; Drug Approval; Drug Therapy, Combination; Humans; Indans; Memantine; N-Methylaspartate; Nootropic Agents; Randomized Controlled Trials as Topic; Risk Factors | 2005 |